Add Vivus (VVUS +4.1%) to the list of companies showing a gain on speculation that demand for...

|By:, SA News Editor

Add Vivus (VVUS +4.1%) to the list of companies showing a gain on speculation that demand for obesity drugs will take off following Orexigen's (OREX +52%) restart on development of Contrave. The momentum buying looks to be led by loose talk the FDA will ease obesity drug standards, which doesn't quite fall in line with analysts and the agency itself (I, II).